68Ga-PSMA PET/CT在MRI与经会阴前列腺活检后能更好地表征局限性前列腺癌:68Ga-PSMA PET/CT引导活检是未来方向吗
该回顾性分析纳入144例接受mpMRI、前列腺活检及68Ga-PSMA PET/CT的患者,比较两种影像对前列腺癌病灶的定位效能。68Ga-PSMA PET/CT与mpMRI对索引病灶检出敏感性相似(83.1% vs 90.1%,p=0.267),但mpMRI漏诊病灶更大(1.66 cm3 vs 0.72 cm3,p=0.034)。68Ga-PSMA PET/CT额外检出率更高,并在mpMRI PIRADS 2患者中识别出11例中9例Gleason≥3+4疾病。
要点
- 68Ga-PSMA PET/CT与mpMRI对索引病灶检出敏感性无显著差异(83.1% vs 90.1%,p=0.267)。
- mpMRI漏诊病灶大于68Ga-PSMA PET/CT漏诊病灶(1.66 cm3 vs 0.72 cm3,p=0.034)。
- 68Ga-PSMA PET/CT在mpMRI PIRADS 2患者中识别出11例中9例Gleason≥3+4疾病。
核心结论
- 尽管一致性高,68Ga-PSMA PET/CT较mpMRI增量改善了肿瘤定位。
- 作者认为68Ga-PSMA PET/CT在诊断流程中可能对mpMRI具有增量价值。
研究设计与样本
- 回顾性分析3年期间接受mpMRI、前列腺活检和68Ga-PSMA PET/CT的患者,共纳入144例。
- 以活检组织病理学评估整个队列的诊断效能,并在部分患者中以根治性前列腺切除标本评估。
- 确定两种模态的病灶一致性和额外检出,包括在mpMRI PIRADS 2扫描的专门队列中。
主要发现
- 索引病灶检出敏感性68Ga-PSMA PET/CT为83.1%,mpMRI为90.1%(p=0.267)。
- mpMRI漏诊病灶为1.66 cm3,68Ga-PSMA PET/CT漏诊病灶为0.72 cm3(p=0.034)。
- 两种影像模态间索引病灶一致性为80.1%,总病灶一致性为67%。
- 额外检出率68Ga-PSMA PET/CT优于mpMRI:索引病灶13.5% vs 4.3%,总病灶18.2% vs 5.4%。
- 两种模态分别漏诊索引病灶2.1%和总病灶12.3%;68Ga-PSMA PET/CT识别出11例PIRADS 2患者中9例随后诊断为Gleason≥3+4疾病。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: 68Ga prostate specific membrane antigen PET/CT (68Ga-PSMA PET/CT) may be superior to multiparametric MRI (mpMRI) for localisation of prostate cancer tumour foci, however the concordance and differences between 68Ga-PSMA PET/CT and mpMRI when applied to all biopsied patients and potential benefit in patients with negative mpMRI is unclear. METHODS: Retrospective analysis of patients undergoing mpMRI, prostate biopsy and 68Ga-PSMA PET/CT over a 3-year period. Diagnostic performance of 68Ga-PSMA PET/CT and mpMRI were assessed using biopsy histopathology for the entire cohort and radical prostatectomy specimen in a subset of patients. Lesion concordance and additional detection of each modality were determined, including in a dedicated cohort of patients with mpMRI PIRADS 2 scans. RESULTS: A total of 144 patients were included in the study. Index lesion/foci detection was similar between 68Ga-PSMA PET/CT and mpMRI (sensitivity 83.1% vs 90.1%; p = 0.267), however lesions missed by mpMRI were larger (1.66 cm3 vs 0.72 cm3; p = 0.034). Lesion detection rates were similar across the biopsy histopathology and radical prostatectomy specimen subset, with a high concordance for index (80.1%) and a moderate concordance for total (67%) lesions between the 2 imaging modalities. The additional detection yield favoured 68Ga-PSMA PET/CT over mpMRI for index (13.5% vs 4.3%) and total (18.2% vs 5.4%) lesions; both modalities missed 2.1% and 12.3% of index and total lesions, respectively. 68Ga-PSMA PET/CT identified 9 of 11 patients with PIRADS 2 mpMRI but subsequently diagnosed with Gleason ≥ 3 + 4 disease. CONCLUSIONS: Despite high concordance rates, 68Ga-PSMA PET/CT incrementally improved tumour localisation compared with mpMRI. These results suggest that 68Ga-PSMA PET/CT may have an incremental value to that of mpMRI in the diagnostic process for prostate.
引用
- Donato P, Morton A, Yaxley J, et al. 68Ga-PSMA PET/CT better characterises localised prostate cancer after MRI and transperineal prostate biopsy: Is 68Ga-PSMA PET/CT guided biopsy the future? Eur J Nucl Med Mol Imaging. 2020. PMID: 31912257. doi:10.1007/s00259-019-04620-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。